Ranbaxy Laboratories has moved higher by 7% to Rs 412 on back of heavy volumes on the bourses. The stock opened at Rs 388 and hit a high of Rs 414, its highest level since June this year, on the National Stock Exchange (NSE).
A combined 6.45 million shares have changed hands on the counter till late noon deals against an average sub 7 million shares that were traded daily in past two weeks on NSE and BSE.
The stock of pharmaceutical company has rallied 23% in past three days, after falling about 13%, it’s sharpest single day fall since May 2009, on Wednesday.
According to Business Standard reports, the drug maker had identified select therapeutic areas and regions, which would drive its future growth.
According to Ranbaxy, the new strategy aims to attain leadership through monetisation of its generic filings, differentiated product strategy, cost optimisation, improvement in productivity, effective use of distribution network and superior manufacturing capability, added report.
A combined 6.45 million shares have changed hands on the counter till late noon deals against an average sub 7 million shares that were traded daily in past two weeks on NSE and BSE.
The stock of pharmaceutical company has rallied 23% in past three days, after falling about 13%, it’s sharpest single day fall since May 2009, on Wednesday.
According to Business Standard reports, the drug maker had identified select therapeutic areas and regions, which would drive its future growth.
According to Ranbaxy, the new strategy aims to attain leadership through monetisation of its generic filings, differentiated product strategy, cost optimisation, improvement in productivity, effective use of distribution network and superior manufacturing capability, added report.
